Grifols Completes the 300 Million Increase in its Private Senior Bond Issue

Grifols has increased its private issue of guaranteed bonds by 300 million euros, completed on April 30th for an amount of one billion euros, as reported this Tuesday by the blood products company. Including this increase, Grifols’ total issuance stands at 1.3 billion euros.

This issue has the same economic terms as the last one, with an annual coupon of 7.5%, maturity in May 2030 and a purchase price of 98.5% of the nominal amount of the bonds. These bonds have the same guarantees and real rights. The funds corresponding to this extension were received this Tuesday and will be used to repay part of the revolving credit line.

In this context, the billion euros previously issued and disbursed have been used to redeem unsecured bonds maturing in May 2025.

Grifols has had Osborne Clarke and Proskauer Rose LLP as legal advisors

The Catalan company has explained that this increase for an amount of 300 million euros and the closing of the previous issue for an amount of one billion euros, both under the same conditions, “reveal the confidence of the financial markets in the operational solidity of Grifols and allow the company to strengthen a long-term financial structure.”

Grifols has had Osborne Clarke and Proskauer Rose LLP as legal advisors , while Bank of America and BNP Paribas have been the placement agents.

The notes were sold in a private placement to qualified institutional buyers pursuant to Section 4 of the US Securities Act of 1933, as amended, and to non-US persons outside the United States pursuant to Regulation S of the Securities Act.

Grifols and PharmaMar drag down the ‘pharma’ companies listed at the end of May

Grifols and PharmaMar are the discordant note among listed pharmaceutical companies. The multinational blood products company and the Spanish laboratory fell 38.8% and 8.5%, respectively, compared to April and compared to the increases of the rest of the companies. The aggregate capitalization of the five pharmaceutical companies in the continuous market stood at 12.9 billion euros in May, which represents a decrease of 4.7% compared to the end of April.

The fall of Grifols coincides with a new attack by the bearish fund Gotham City Research in mid-May that weighed down the value of the shares of the Catalan multinational blood products by 4%. All this, despite the fact that its quarterly results showed profits compared to the losses of 2023 .

The Spanish company obtained a net profit of 21.4 million euros during the first quarter of this year, compared to losses of 108.2 million in the first quarter of 2023 , a period affected by extraordinary restructuring costs, and placed its net debt according to balance sheet at 10.9 billion euros.

__

(Featured image by Ibrahim Boran via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce and PlantaDoce. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us